REG - Proteome Sciences - Director/PDMR Shareholding <Origin Href="QuoteRef">PRM.L</Origin>

Proteome SciencesAnnouncement

08/11/2017 12:01

RNS Number : 9351V
Proteome Sciences PLC
08 November 2017
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 6 November 2017, it purchased 20,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.17p per Ordinary Share (the "Purchase"). Following the Purchase, Vulpes has a total direct and indirect interest in 55,217,431 equivalent to 18.71% of Proteome Sciences' total issued share capital.
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 55,217,431 Ordinary Shares of the Company representing 18.71% of the issued share capital of the Company.
1. 
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Vulpes Life Sciences Fund
2. 
Reason for the Notification
a)
Position/status
PCA of Martin Diggle (NED)
b)
Initial notification/Amendment
Initial notification
3. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Proteome Sciences plc
b)
LEI
213800Q62ICXANKU2986
4. 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the Financial instrument, type of instrument
Ordinary Shares of 1p each
Identification code
GB0003104196
b)
Nature of the transaction
Purchase of shares
c)
Price(s) and volume(s)
20,000 Ordinary Shares at 3.17p per Ordinary Share
d)
Aggregated information:
 Aggregated volume
 Price
20,000 Ordinary Shares of 1p each purchased at 3.17p per Ordinary Share
e)
Date of the transaction
6 November 2017
f)
Place of the transaction
London Stock Exchange, AIM Market (XLON)
For further information: 
Proteome Sciences plc 
Jeremy Haigh, Chief Executive Officer Tel: +44 (0)20 7043 2116
Ian Pike, Chief Scientific Officer 

Stefan Fuhrman, Interim Finance Director 
finnCap Limited (Nominated Adviser/Broker)
Geoff Nash/James Thompson
Tel: +44 (0)20 7220 0500
Tony Quirke (broking)
IFC Advisory (Financial PR and IR)
Tim Metcalfe/Graham Herring/Miles Nolan
 Tel: +44 (0)20 3053 8671

 
Notes for editors:
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHFSSFFAFWSELF